tuneTypical Dose
500-600
Fatty Acid
Short-chain fatty acids
Butyrate (primary supplemental SCFA)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
4-12 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Short-chain fatty acids are microbial metabolites used to support gut and immune function.
Current human evidence is strongest in selected GI-disease contexts and remains mixed in broader populations. Treat as a targeted adjunct and reassess benefit after a time-boxed trial.
Butyrate supports epithelial energy metabolism and can modulate inflammatory pathways, with adjunctive clinical benefits in selected GI contexts.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Adjunctive improvement in selected ulcerative-colitis inflammatory and symptom endpoints
- Improvement in selected IBS symptoms in some adult/pediatric cohorts
Secondary Outcomes
- Mixed efficacy across IBD populations
- Effects are formulation-specific and not generalizable to all SCFAs
Safety
Contraindications and Interactions
Contraindications
- Severe active GI disease without specialist management
- Intolerance to formulation excipients
- Use as monotherapy in uncontrolled IBD
Side effects
- Mild GI upset
- Bloating/stool changes
- Taste/odor tolerability issues
Interactions
- Additive GI effects with multi-biotic stacks
- Coordinate with anti-inflammatory/IBD regimens
- Sodium-form caution in sodium-restricted patients
Avoid if
- Inability to monitor clinical response
- Progressive flare symptoms requiring urgent care
- Empiric stacking of multiple new gut supplements
Evidence
Study-level References
short-chain-fatty-acids-SRC-001RCT
Sourceopen_in_newKarlowicz K, Lewandowski K, Kaniewska MA, et al. Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis. Med Sci Monit. 2025;31. doi:10.12659/MSM.948912. PMID:41422374.
Population: Adults with active mild-to-moderate ulcerative colitis
Dose protocol: Microencapsulated sodium butyrate 300 mg twice daily vs placebo for 8 weeks.
Key findings: Improved clinical improvement/remission, biochemical remission, and endoscopic improvement rates.
Notes: Short duration, adjunctive-therapy context.
Paper content
This multicenter double-blind RCT of 98 patients with mild-to-moderate ulcerative colitis found that microencapsulated sodium butyrate (600 mg/day) as add-on therapy for 8 weeks significantly improved clinical remission (31.4%), clinical improvement (51%), and biochemical remission (42.2%) compared to placebo.
short-chain-fatty-acids-SRC-002Double-blind randomized controlled trial
Sourceopen_in_newFiroozi D, et al. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Lipids Health Dis. 2024;23(1):216. doi:10.1186/s12944-024-02203-z. PMID:39003477.
Population: Adults with active ulcerative colitis
Dose protocol: Oral sodium butyrate vs placebo for 12 weeks (reported dosing format requires careful interpretation).
Key findings: Reduced inflammatory markers, improved sleep/QoL, and gene-expression changes.
Notes: Small cohort and dose-reporting ambiguity.
Paper content
Favorable directionality on inflammatory and selected symptom endpoints.
short-chain-fatty-acids-SRC-003Randomized double-blind placebo-controlled trial.
Sourceopen_in_newFiroozi D, et al. Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors in Patients With Active Ulcerative Colitis: A Double-Blind Randomized Controlled Trial. J Nutr Metab. 2025;2025:3165876. doi:10.1155/jnme/3165876. PMID:40123849.
Population: 36 adults with active UC.
Dose protocol: Oral sodium butyrate vs placebo for 12 weeks.
Key findings: Improved disease activity and anxiety/depression scale outcomes with reduced inflammatory indices.
Notes: Small sample and single-region setting.
Paper content
Improved disease activity and anxiety/depression scale outcomes with reduced inflammatory indices.
short-chain-fatty-acids-SRC-004Randomized controlled trial
Sourceopen_in_newBanasiewicz T, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013;15(2):204-209. doi:10.1111/j.1463-1318.2012.03152.x. PMID:22738315.
Population: Adults with IBS
Dose protocol: Microencapsulated sodium butyrate adjunct vs placebo for 12 weeks.
Key findings: Reduced frequency of selected IBS symptoms.
Notes: Symptom-frequency improvements stronger than symptom-severity outcomes.
Paper content
Reduced abdominal pain frequency in treated group.
short-chain-fatty-acids-SRC-005Randomized double-blind placebo-controlled trial.
Sourceopen_in_newCristofori F, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial. J Pediatr Gastroenterol Nutr. 2025;81(3):551-561. doi:10.1002/jpn3.70154. PMID:40635319.
Population: 51 children/adolescents with IBS (Rome IV).
Dose protocol: Calcium butyrate 500 mg/day vs placebo for 8 weeks plus 4-week follow-up.
Key findings: Significant treatment success and sustained symptom-score improvement.
Notes: Pediatric-specific cohort limits adult generalization.
Paper content
Significant treatment success and sustained symptom-score improvement.
short-chain-fatty-acids-SRC-006Multicenter randomized placebo-controlled trial.
Sourceopen_in_newPietrzak A, et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022;14(16):3283. doi:10.3390/nu14163283. PMID:36014789.
Population: 72 pediatric patients with newly diagnosed colonic IBD.
Dose protocol: Sodium butyrate 150 mg twice daily vs placebo for 12 weeks.
Key findings: No significant added efficacy versus placebo.
Notes: Newly diagnosed pediatric context may differ from adult active UC populations.
Paper content
No significant added efficacy versus placebo.
short-chain-fatty-acids-SRC-007Randomized double-blind placebo-controlled pilot study.
Sourceopen_in_newVernia P, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000;45(5):976-981. doi:10.1023/a:1005537411244. PMID:10795763.
Population: 30 adults with mild-to-moderate UC (25 completers).
Dose protocol: Colonic-targeted oral sodium butyrate 4 g/day + mesalazine vs mesalazine + placebo for 6 weeks.
Key findings: Favorable trend for combined therapy, not consistently significant between groups.
Notes: Small pilot with older methodology.
Paper content
Favorable trend for combined therapy, not consistently significant between groups.
short-chain-fatty-acids-SRC-008Randomized double-blind placebo-controlled trial.
Sourceopen_in_newBanasiewicz T, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Med. 2024;14(1):6. doi:10.3390/jcm14010006. PMID:39797089.
Population: 120 adults with IBS.
Dose protocol: Multi-component biotic mixture containing microencapsulated sodium butyrate for 12 weeks.
Key findings: Improved adequate-relief and some symptom domains, mixed across global severity/QoL metrics.
Notes: Multi-ingredient intervention limits pure butyrate attribution.
Paper content
Improved adequate-relief and some symptom domains; mixed across global severity/QoL metrics.
short-chain-fatty-acids-SRC-009Double-blind, placebo-controlled pilot study.
Sourceopen_in_newFacchin S, Vitulo N, Calgaro M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020;32(10):e13914. doi:10.1111/nmo.13914. PMID:32476236.
Population: Adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis) and healthy volunteers.
Dose protocol: Microencapsulated sodium butyrate versus placebo for 2 months alongside standard IBD therapy.
Key findings: Increased SCFA-producing bacteria in UC and butyrogenic bacteria in CD patients, with improved quality of life in UC subgroup.
Notes: Microbiome-endpoint study. Provides mechanistic support for butyrate in IBD.
Paper content
This pilot study tested microencapsulated sodium butyrate versus placebo for 2 months in 49 IBD patients and 18 healthy controls. Using 16S sequencing, the authors found that butyrate supplementation increased SCFA-producing bacteria in UC patients and butyrogenic bacteria in CD patients. Quality of life improved in the UC subgroup. The study provides mechanistic support for butyrate supplementation in IBD by showing favorable shifts in microbiota composition, though the pilot size and microbiome-endpoint focus limit clinical conclusions.